






























MASTER TRIAL LIST

FEBRUARY 2023

 New or ReOpened Trials
 No Trials Currently Available

JUST IN TIME TRIALS (JIT)

 AML	 ANAL	 ALL
 APL	 BILIARY	 BLADDER-UROTHELIAL
 BRAIN	 BREAST/ GYN	 CANCER CONTROL
 CLL	 CML	 COLON-RECTAL
 ESOPHAGEAL - GASTRIC	 HEAD & NECK	 LYMPHOMA
 MDS	 MELANOMA	 MERKEL
 MOLECULAR STUDIES	 MULTIPLE MYELOMA	 NEUROENDOCRINE
 NSCLC	 PANCREATIC	 PROSTATE
 RADIATION TRIALS	 RENAL CELL	 SMALL CELL LUNG CANCER

Updated 2.5.23

RADIATION LOCATIONS:

OSF Glen Oak - OSF main hospital
OSF Route 91 (attached to Illinois CancerCare)
UPHM - Unity Point Health Methodist
Galesburg - Western Illinois Cancer Treatment Center
SJMC - St Joseph Medical Center



JUST IN TIME (JIT) TRIALS

*Contact Disease Specific Navigator

Multi-Disease Site: Advanced/Metastatic Solid Tumors

RAIN-3202

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors

ALL

EA9213

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)

Biliary

EA2187

Temporarily closed Phase II study of Pevonedistat in Combincatoin with Carbo and paclitaxel in advanced intrahepatic cholangiocarcinoma.

Endometrial

GY026

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

Genitourinary - Rare

A031702

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors (*temp closed cohorts - small cell carcinoma/neuroendorine & adenocarcinoma of bladder, penile, and misc GU tract variants, renal medullary carcinoma, and rare GU*)

Head & Neck

EA3191

A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features

HN010

A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer

Lung

<u>S1934</u>	Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer. NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors)
Neuroendocrine	
<u>S2104</u>	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Pancreas	
<u>S2104</u>	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Rectal	
<u>EA2201</u>	(RT at Glen Oak, UPHM, Galesburg) A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Renal Cell Carcinoma	
<u>S2200</u>	A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)
Skin	
<u>A091802</u>	Phase II randomized Trial of Avelumab plus cetuximab versus avelumab alone in advanced cutaneous Squamous cell carcinoma of skin

MASTER TRIAL LIST

FEBRUARY 2023

[MENU](#)

AML

Navigator - Heather x3661



MASTER TRIAL LIST

FEBRUARY 2023



ANAL

Navigator - Carrie x3621

<u>EA2176</u>	A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
<u>EA2182</u>	(RT at UPHM and Glen Oak) A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)



ILLINOIS
CANCERCARE, P.C.

Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

FEBRUARY 2023

[MENU](#)

APL

Navigator - Heather x3661

There are no trials available at this time



ILLINOIS
CANCERCARE, P.C.

Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

FEBRUARY 2023

[MENU](#)

ACUTE LYMPHOBLASTIC LEUKEMIA

[Navigator - Heather x3661](#)

[EA9213 - JIT Trial](#)

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)



MASTER TRIAL LIST

FEBRUARY 2023



BILIARY

Navigator - Carrie x3621

[EA9213 - JIT Trial](#)

Temporarily closed | Phase II stud of Pevonedistat in Combincatoin with Carbo and Paclitaxel in advanced intrahepatic cholangiocarcinoma.



MASTER TRIAL LIST

FEBRUARY 2023

MENU

BLADDER / UROTHELIAL

Navigator - Carrie x3621

ADJUVANT / NEOADJUVANT

<u>EA8185</u>	(RT pending at Glen Oak & Rt-91) Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)
<u>S1806</u>	(RT at Glen Oak, SJMC, UPHM and Galesburg) Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
<u>S2011</u>	Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL
<h3>METASTATIC</h3>	
<u>A032001</u>	Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer
<u>A032002</u>	(RT at Glen Oak) Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)



MASTER TRIAL LIST

FEBRUARY 2023



BRAIN

Navigator - Carrie x3621

<u>A071702</u>	A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
<u>BN007</u>	Temporarily Closed (RT at UPHM, Glen Oak, Galesburg) A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
<u>BN011</u>	(RT credentialing pending) A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
<u>N0577</u>	(RT at Glen Oak, RT 91, and UPHM) Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma



BREAST

Navigator - Angie x3613

DCIS

No trials at this time

NEO/ADJUVANT TREATMENT

S1706*

Not Actively Screening - Contact Navigator - A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (**All biomarker subgroups eligible**) | *JIT TRIAL - expect 1 week delay to consent pt

Neo/Adjuvant - HER2 Positive

A011801

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

EA1181

Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response (CompassHER2-pCR) (*Closed to Her2+/ER+ w/ tumor 2.1-3cm and node negative*)

Neo/Adjuvant - Hormone Receptor Positive / HER2 Negative

BR007

(RT at Galesburg, Glen Oak, Rt 91, UPHM, SJMC) Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

Neo/Adjuvant - Triple Negative (no trials at this time)

METASTATIC TREATMENT

Metastatic - HER2 Positive (no trials at this time)

Metastatic - Hormone Receptor Positive / HER2 Negative

S1703

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

S2007

Not Actively Screening - contact Navigator- A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases

Metastatic - Triple Negative (no trials at this time)

SURGERY / RADIATION ONLY

<u>MA.39</u>	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (<i>RT: Glen Oak and UPHM</i>)
CANCER CONTROL (Breast only)	
<u>A191901</u>	Temporarily Closed (Peoria, Bloomington, Galesburg, Ottawa, Pekin, and Peru) Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (<i>only enrolling African American women</i>)
<u>A211901</u>	Not Actively Screening - Contact Navigator Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<u>A212102</u>	(Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash) Blinded Reference Set for Multicancer Early Detection Blood Tests (<i>healthy cohort: closed to caucasian women age <60</i>)
<u>A222004</u>	Not Actively Screening - Contact Navigator A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
<u>EAQ202</u>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (<i>breast, leukemia, and lymphoma cohorts closed to accrual</i>)
<u>S2010</u>	NEW! A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
<u>S2108CD</u>	(Peoria, Bloomington, Galesburg, Canton, Ottawa) A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
<u>S1912CD</u>	Not Actively Screening - Contact Navigator A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
<u>S2013</u>	(Peoria, Bloomington, Galesburg, Pekin, Washington) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT)
<u>URCC 16070</u>	Treatment of Refractory Nausea- for breast cancer patients.
<u>URCC-18007</u>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue- <i>at least 2 months out from surgery/tx/radiation</i>
<u>URCC 21038</u>	(Peoria Only) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<u>WF-1901</u>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

NRG - GY023

Temporarily Closed A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor (Durvalumab) MEDI4736 in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or (Durvalumab) MEDI4736 and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

CANCER CONTROL

MULTI-DISEASE SITES

<u>A211901</u>	<u>Not Actively Screening - Contact Navigator</u> Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<u>A212102</u>	(Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash) Blinded Reference Set for Multicancer Early Detection Blood Tests (<i>healthy cohort: closed to caucasian women age <60</i>)
<u>A222004</u>	<u>Not Actively Screening - Contact Navigator</u> A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
<u>EAQ202</u>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (<i>breast, leukemia, and lymphoma cohorts closed to accrual</i>)
<u>S1912CD</u>	<u>Not Actively Screening - Contact Navigator</u> A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
<u>S2013</u>	(Peoria, Bloomington, Galesburg, Pekin, Washington) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT)
<u>S2108CD</u>	(Peoria, Bloomington, Galesburg, Canton, Ottawa) A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
<u>URCC-18007</u>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<u>URCC 21038</u>	(Peoria only) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<u>WF-1901</u>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

BREAST

<u>A191901</u>	Temporarily Closed (Peoria, Bloomington, Galesburg, Ottawa, Pekin, and Peru) Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (<i>only enrolling African American women</i>)
<u>S2010</u>	NEW! A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
<u>URCC 16070</u>	Treatment of Refractory Nausea- for breast cancer patients.

LUNG

	Nothing currently available for Lung only - <i>See Multi-Disease Cancer Control trials ABOVE.</i>
--	---

COLORECTAL

<u>A221805</u>	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
<u>WF-1806</u>	(M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer
BRAIN	
<u>WF-1801</u>	A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
REGISTRY	
Navigator - Heather 243-3661	
<u>Connect Myeloid</u>	The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. <i>(enrolling low risk MDS only)</i>
<u>NHLBI-MDS</u>	(Peoria, Bloomington and Galesburg only) -The National Myelodysplastic Syndromes (MDS) Study



MASTER TRIAL LIST

FEBRUARY 2023

[MENU](#)

CARCINOID

Navigator - Ashton x3611
Carrie x3621

[A021602](#)

Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo In Patients With Advanced Neuroendocrine Tumors After progression on Prior Therapy (CABINET)



MASTER TRIAL LIST

FEBRUARY 2023



CLL

Navigator - Heather x3661

no trials at this time

1st Line

2nd Line, 3rd Line, etc.



MASTER TRIAL LIST

FEBRUARY 2023



CML

Navigator - Heather x3661

No trials at this time

MASTER TRIAL LIST

MENU

FEBRUARY 2023

COLON / RECTAL

Navigator - Carrie x3621

Adjuvant

C-14	(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington) Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease (CORRECT-MRD II)
EA2201 - JIT	(RT at Glen Oak, UPHM, Galesburg) A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
GI005	Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
GI008	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Metastatic

S2107	Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
-----------------------	--

CANCER CONTROL (Colorectal only)

A211901	Not Actively Screening - Contact Navigator Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
A212102	Blinded Reference Set for Multicancer Early Detection Blood Tests (<i>healthy cohort: closed to caucasian women age <60</i>)
A221805	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
A222004	Not Actively Screening - Contact Navigator A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
EAQ202	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (<i>breast, leukemia, and lymphoma cohorts closed to accrual</i>)
A212102	(Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash) Blinded Reference Set for Multicancer Early Detection Blood Tests
S1912CD	Not Actively Screening - Contact Navigator A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

<u>S2013</u>	(Peoria, Bloomington, Galesburg, Pekin, Washington) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT)
<u>S2108CD</u>	(Peoria, Bloomington, Galesburg, Canton, Ottawa) A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
<u>URCC-18007</u>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<u>URCC 21038</u>	(Peoria Only) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<u>WF-1901</u>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
<u>WF-1806</u>	(M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer



MASTER TRIAL LIST

FEBRUARY 2023



ESOPHAGEAL- GASTRIC

Navigator - Carrie x3621

[A022102](#)

NEW! Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma

HEAD & NECK

Navigator - Ashton x3611

<u>EA3161</u>	(RT at Glen Oak, UPH, Galesburg) A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
<u>EA3191 - JIT</u>	A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
<u>HN005</u>	Temporarily Closed (RT at UPHM, Galesburg, Glen Oak) A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
<u>HN009</u>	(RT at UPHM) Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m ²) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m ²) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
<u>HN010 - JIT Trial</u>	A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer
<u>S2101</u>	Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

LYMPHOMA

HL

No HL trials at this time

NHL

EA4181

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients \leq 70 Years Old With Untreated Mantle Cell Lymphoma (*Arm 3 closed to enrollment*)



MASTER TRIAL LIST

FEBRUARY 2023



MDS

Navigator - Heather x3661

<u>Connect Myeloid</u>	The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. <i>(enrolling low risk MDS only)</i>
<u>NHLBI-MDS</u>	(Peoria, Bloomington and Galesburg only) -The National Myelodysplastic Syndromes (MDS) Study



MASTER TRIAL LIST

FEBRUARY 2023

MENU

MELANOMA

Navigator - Carrie x3621

S2101

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study



MASTER TRIAL LIST

FEBRUARY 2023

MENU

MERKEL

Navigator - Carrie x3621

EA6174

(RT at Glen Oak, UPHM, Galesburg) A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma



MASTER TRIAL LIST

FEBRUARY 2023

MENU

MOLECULAR STUDIES

*Contact Disease Specific Navigator

<u>A151804</u>	Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
<u>S1823</u>	A Study of miRNA 371 in Patients With Germ Cell Tumor (<i>closed to high risk pts or pts on chemo for testicular cancer</i>)
<u>TP-CA-003 (Sculptor)</u>	(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington) A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)
<u>TPX-0005-01 (TRIDENT-1)</u>	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

MASTER TRIAL LIST

FEBRUARY 2023

MENU

MULTIPLE MYELOMA

Navigator - Heather x3661

EAA173	Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
<u>S1803</u>	Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

MASTER TRIAL LIST

FEBRUARY 2023

MENU

NEUROENDOCRINE

Navigator - Carrie x3621

<u>A021602</u>	Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo In Patients With Advanced Neuroendocrine Tumors After progression on Prior Therapy (CABINET)
<u>A021804</u>	A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
<u>S2104 - JIT Trial</u>	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

NSCLC

Navigator - Ashton x3611

ADJUVANT / NEOADJUVANT

<u>A081801</u>	Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ALCHEMIST substudy- <i>Must be enrolled on ALCHEMIST and this substudy prior to start of tx</i>).
<u>A151216</u>	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).
<u>EA5181</u>	(RT at Glen Oak, UPHM and Galesburg) Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC (credentialing pending at Rt-91)
<u>S1914</u>	(RT at Glen Oak, UPHM, Galesburg) Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
<u>S1934 - JIT Trial</u>	Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer. NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors)

METASTATIC - 1st Line

<u>EA5182</u>	Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
<u>GS-US-626-6216 (STAR-121)</u>	(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington) A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
<u>MK 7684A-003</u>	Screening by referral only (Peoria only) A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

METASTATIC - 2nd/3rd Line

<u>ADXS-503-101</u>	A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer (Part 2B)
<u>EA5162</u>	Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
<u>LUNGMAP</u>	A Master Protocol To Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated NSCLC. (SUB-STUDIES: S1800D - A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy; S1900E - A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer); S1900F - A Randomized Phase II Study of Carboplatin and Pemetrexed w/ or w/o Selpercatinib in Participants With Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy)

<u>A211901</u>	<u>Not Actively Screening - Contact Navigator</u> Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<u>A212102</u>	(Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash) Blinded Reference Set for Multicancer Early Detection Blood Tests (<i>healthy cohort: closed to caucasian women age <60</i>)
<u>A222004</u>	<u>Not Actively Screening - Contact Navigator</u> A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
<u>EAQ202</u>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (<i>breast, leukemia, lymphoma cohorts closed to accrual</i>)
<u>S2108CD</u>	(Peoria, Bloomington, Galesburg, Canton, Ottawa) A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
<u>S1912CD</u>	<u>Not Actively Screening - Contact Navigator</u> A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
<u>S2013</u>	(Peoria, Bloomington, Galesburg, Pekin, Washington) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT)
<u>URCC-18007</u>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<u>URCC 21038</u>	(Peoria Only) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<u>WF-1901</u>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)



MASTER TRIAL LIST

FEBRUARY 2023



PANCREATIC

Navigator - Carrie x3621

<u>EA2186</u>	A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
<u>EA2192</u>	A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (APOLLO)
<u>S2001</u>	Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
<u>S2104 - JIT Trial</u>	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

MASTER TRIAL LIST

FEBRUARY 2023

MENU

PROSTATE

Navigator - Carrie x3621

ADJUVANT

[GU008](#)

(RT at Glen Oak, UPHM) Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy*

[GU009](#)

(RT at Glen Oak, Galesburg, UPHM, Rt 91) Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (**PREDICT-RT***)

[GU010](#)

(RT at UPHM) Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

METASTATIC

[A032101](#)

A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM

[C2321001](#)

(Peoria only) A Phase I Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL)

[A031902 / CASPAR](#)

A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

<u>GU011</u>	(RT at Glen Oak and UPHM) A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadioTHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
<u>S1802</u>	(RT at Glen Oak, SJMC & UPHM) Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

MASTER TRIAL LIST

FEBRUARY 2023

MENU

RENAL CELL

Navigator - Carrie x3621

<u>A031704</u>	PD-Inhibitor (nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
<u>MK 6482-011</u>	(Peoria, Bloomington, Galesburg, Pekin) An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
<u>S2200 - JIT Trial</u>	A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)

RADIATION TRIALS

Navigator - Jessica x3615

CANCER CONTROL	
<u>WF-1801</u>	A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
ANAL	
<u>EA2182</u>	(UPHM and Glen Oak) A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
BLADDER	
<u>A032002</u>	(RT at Glen Oak) Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)
<u>EA8185</u>	(RT pending at Glen Oak & Rt-91) Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)
<u>S1806</u>	(Glen Oak, SJMC, UPHM and Galesburg) Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
BRAIN	
<u>BN007</u>	Temporarily Closed (UPHM, Glen Oak, Galesburg) A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
<u>N0577</u>	(Glen Oak, RT 91, and UPHM) Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
BRAIN METS	
<u>CCTG CE.7</u>	(UPHM & Glen Oak)- A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
BREAST	

<u>BR007</u>	(Galesburg, Glen Oak, Rt 91, UPHM, SJMC) Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
<u>MA.39</u>	(Glen Oak and UPHM) Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
HEAD & NECK	
<u>EA3161</u>	(Glen Oak, UPH, Galeburg) A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
<u>HN005</u>	Temporarily Closed (UPHM, Galesburg, Glen Oak) A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
<u>HN009</u>	(RT at UPHM) Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m ²) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m ²) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
HODGKIN'S LYMPHOMA	
<u>S1826</u>	Temporarily Closed (Glen Oak, Rt-91, UPHM) A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MERKEL CELL	
<u>EA6174</u>	(Glen Oak, UPHM and Galesburg) A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
NSCLC	
<u>EA5181</u>	(UPHM, Glen Oak and Galesburg) Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC (credentialing pending at Rt 91)
<u>S1914</u>	(Glen Oak, UPHM, Galesburg) Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
PROSTATE	

<u>GU008</u>	(RT at Glen Oak, UPHM) Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i>
<u>GU009</u>	(RT at Glen Oak, Galesburg, UPHM, Rt 91) Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
<u>GU010</u>	(RT at UPHM) Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
<u>GU011</u>	(RT at Glen Oak & UPHM) A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiothERapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
<u>S1802</u>	(Glen Oak, SJMC & UPHM) Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
<u>WF-1802</u>	(Glen Oak, Rt-91, UPHM, Galesburg) Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
SCLC	
<u>NRG CC009</u>	(Glen Oak, UPHM) - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
<u>S1827</u>	(Glen Oak, UPHM, Galesburg, SJMC) A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer

SMALL CELL LUNG CANCER

Navigator - Ashton x3611

<p><u>NRG CC009</u></p>	<p>(RT at Glen Oak, UPHM) - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer</p>
<p><u>GO43104</u></p>	<p>(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington) A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin In Combination With Atezolizumab Compared With Atezolizumab As Maintenance Therapy In Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab</p>
<p><u>S1827</u></p>	<p>(RT at Glen Oak, UPHM, Galesburg, SJMC) A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer</p>
<p><u>TP-CA-003 (Sculptor)</u></p>	<p>(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington) A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)</p>